Skip to main content
NCBI home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2002 Dec 16;69(2):188–194. doi: 10.1002/jmv.10286

Synergistic antiviral effect of a combination of mouse interferon‐α and interferon‐γ on mouse hepatitis virus

Uichiro Fuchizaki 1, Shuichi Kaneko 1,✉, Yasunari Nakamoto 1, Yoshihiro Sugiyama 2, Kenichi Imagawa 3, Mikio Kikuchi 2, Kenichi Kobayashi 1
PMCID: PMC7166598  PMID: 12683406

Abstract

Although interferon (IFN)‐α and IFN‐γ have been reported to exhibit a synergistic antiviral effect through the different signaling pathways in vitro, their therapeutic efficacy is not well defined in vivo. The current study was carried out to investigate the combined antiviral effect in a model of mouse hepatitis virus Type 2 (MHV‐2) infection, in which fulminant hepatitis is developed. MHV‐2 was injected intraperitoneally into 4‐week‐old ICR mice, IFN or the vehicle was administered intramuscularly for 5 days, and the antiviral effect was evaluated based on survival periods, liver histology, serum alanine transaminase (ALT) levels, and MHV‐2 virus titers in the liver tissues. The animals in the group treated with a combination of IFN‐α and IFN‐γ survived for longer periods than the groups treated with IFN‐α alone and IFN‐γ alone (IFN‐α 103 (IU/mouse)/‐γ 103 vs. IFN‐α 103, P < 0.005; IFN‐α 103/‐γ 103 vs. IFN‐γ 103, P < 0.001). This is consistent with the lower levels of hepatocellular necrosis and serum ALT and the decreased titers of MHV‐2 virus in the liver tissues (48 hr, P < 0.001; 72 hr, P < 0.001). These findings indicate that a combination of IFN‐α and IFN‐γ exhibits a synergistic antiviral effect on MHV‐2 infection. The biology of MHV‐2 is quite different from that of human hepatitis viruses; however, these results suggest the beneficial combined therapy of IFN‐α and IFN‐γ for the treatment of human viral hepatitis. J. Med. Virol. 69:188–194, 2003. © 2003 Wiley‐Liss, Inc.

Keywords: mouse hepatitis virus, interferon‐α, interferon‐γ, antiviral effect, synergy

REFERENCES

  1. Allen G, Diaz MO. 1996. Nomenclature of the human interferon proteins. J Interferon Cytokine Res 16: 181–184. [DOI] [PubMed] [Google Scholar]
  2. Bergamini A, Bolacchi F, Cepparulo M, Demin F, Uccella I, Bongiovanni B, Ombres D, Angelico F, Liuti A, Hurtova M, Francioso S, Carvelli C, Cerasari G, Angelico M, Rocchi G. 2001. Treatment with ribavirin and interferon‐alpha reduces interferon‐gamma expression in patients with chronic hepatitis C. Clin Exp Immunol 123: 459–464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA, Blatt LM. 2000. Inhibition of hepatitis C virus (HCV)‐RNA‐dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 31: 769–776. [DOI] [PubMed] [Google Scholar]
  4. Compton SR, Barthold SW, Smith AL. 1993. The cellular and molecular pathogenesis of coronavirus. Lab Anim 43: 15–28. [PubMed] [Google Scholar]
  5. Darnell JE Jr, Kerr IM, Stark GR. 1994. Jak‐STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415–1421. [DOI] [PubMed] [Google Scholar]
  6. Davis GL, Esteban‐Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling H. 1998. Interferon‐alpha 2a alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339: 1493–1499. [DOI] [PubMed] [Google Scholar]
  7. Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 95: 15623–15628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77–81. [DOI] [PubMed] [Google Scholar]
  9. Fujiwara K, Mochida S, Mtsuo S. 1998. Randomized control of trial of interferon‐beta injections at 12‐h intervals as a therapy for chronic hepatitis C. Hepatol Res 12: 240–251. [Google Scholar]
  10. Heathcote EJ, Keeffe EB, Lee SS, Feinmann SV, Tong MJ, Reddy KR, Albert DG Jr, Witt K, Blatt LM. 1998. Re‐treatment of chronic hepatitis C with consensus interferon. Hepatology 27: 1136–1143. [DOI] [PubMed] [Google Scholar]
  11. Hirano N, Fujiwara K, Matsumoto M. 1976. Mouse hepatitis virus (MHV‐2): plaque assay and propagation in mouse cell line DBT cells. Jpn J Microbiol 20: 219–225. [PubMed] [Google Scholar]
  12. Hirano N, Murakami T, Taguchi F, Fujiwara K, Matsumoto M. 1981. Comparison of mouse hepatitis virus strains for pathogenicity in weanling mice infected by various routes. Arch Virol 70: 69–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jones W, Cohen RB. 1962. The effect of a murine hepatitis virus on the liver. Am J Pathol 41: 329–347. [PMC free article] [PubMed] [Google Scholar]
  14. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara K, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y. 1995. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 21: 291–297. [PubMed] [Google Scholar]
  15. Katayama K, Kasahara A, Sasaki Y, Kashiwagi T, Naito M, Masuzawa M, Katoh M, Yoshihara H, Kamada T, Mukuda T, Hijioka T, Hori M, Hayashi N. 2001. Immunological response to interferon‐gamma priming prior to interferon‐alpha treatment in refractory chronic hepatitis C in relation to viral clearance. J Viral Hepat 8: 180–185. [DOI] [PubMed] [Google Scholar]
  16. Kato Y, Noda Y, Unoura M, Tanaka N, Kobayashi K, Hattori N, Kobayashi S. 1986. Effect of exogenous mouse interferon on murine fulminant hepatitis induced by mouse hepatitis virus Type 2. Dig Dis Sci 31: 177–180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Krampera M, Fattovich G, Scupoli MT, Pizzolo G. 2000. Early decrease of interferon‐gamma+ and interleukin‐2+ T cells during combination treatment with interferon‐alpha and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 95: 3670–3673. [DOI] [PubMed] [Google Scholar]
  18. Kumashiro R, Ide T, Sasaki M, Murashima S, Suzuki H, Hino T, Morita Y, Miyajima I, Ogata K, Tanaka E, Yoshida H, Tanikawa K, Sata M. 2002. Interferon‐gamma brings additive anti‐viral environment when combined with interferon‐alpha in patients with chronic hepatitis C. Hepatol Res 22: 20–26. [DOI] [PubMed] [Google Scholar]
  19. Kyuwa S, Tagawa Y, Machii K, Shibata S, Doi K, Fujiwara K, Iwakura Y. 1998a. MHV‐induced fetal peritonitis in mice lacking IFN‐gamma. Adv Exp Med Biol 440: 445–450. [DOI] [PubMed] [Google Scholar]
  20. Kyuwa S, Tagawa Y, Shibata S, Doi K, Machii K, Iwakura Y. 1998b. Murine coronavirus‐induced subacute fetal peritonitis in C56BL/6 mice deficient in gamma interferon. J Virol 72: 9286–9290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lee HJ, Shieh CK, Gorbalenya AE, Koonin EV, La Monica N, Tuler J, Bagdzhadzhyan A, Lai MM. 1991. The complete sequence (22 kilobases) of murine coronavirus gene 1 encoding the putative proteases and RNA polymerase. Virology 180: 567–582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Levy DE, Lew DJ, Decker T, Darnell JE Jr. 1990. Synergistic interaction between interferon‐alpha and interferon‐gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J 9: 1105–1111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Liu MF, Ning Q, Pope M, Mosmann T, Leibowitz J, Ding JW, Fung LS, Rotstein O, Gorczynski R, Levy GA. 1998. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre‐existing antibody partially protects against primary infection. Adv Exp Med Biol 440: 415–423. [DOI] [PubMed] [Google Scholar]
  24. Macejak DG, Jensen KL, Jamison SE, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA, Blatt LM. 2000. Inhibition of hepatitis C virus (HCV)‐RNA‐dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 31: 769–776. [DOI] [PubMed] [Google Scholar]
  25. Marcellin P, Pouteau M, Martinot‐Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP. 1995. Lack of benefit of escalating dosage of interferon alpha in patients with chronic hepatitis C. Gastroenterology 109: 156–165. [DOI] [PubMed] [Google Scholar]
  26. Martinot‐Peignoux M, Marcellin P, Pouteau M, Casteau M, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V. 1995. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 22: 1050–1056. [PubMed] [Google Scholar]
  27. Matsumoto M, Tanaka N, Harada H, Kimura T, Yokochi T, Kitagawa M, Schindler C, Taniguchi T. 1999. Activation of the transcription factor ISGF3 by interferon‐gamma. Biol Chem 380: 699–703. [DOI] [PubMed] [Google Scholar]
  28. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling M‐H, Cort S, Albrecht JK. 1998. Interferon alpha‐2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis International Therapy Group. N Engl J Med 339: 1485–1492. [DOI] [PubMed] [Google Scholar]
  29. Mizokami M, Orito E, Gibo Y, Ohba K, Ohno T, Lau JY. 1996. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon‐alpha 2a therapy in Japanese patients with chronic hepatitis C. Liver 16: 23–27. [DOI] [PubMed] [Google Scholar]
  30. Mizukoshi E, Kaneko S, Yanagi M, Ohno H, Kobayashi K. 1999. Upregulation of Type I interferon receptor by IFN‐gamma. J Interferon Cytokine Res 19: 1019–1023. [DOI] [PubMed] [Google Scholar]
  31. Samuel CE. 1991. Antiviral actions of interferon. Interferon‐regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183: 1–11. [DOI] [PubMed] [Google Scholar]
  32. Schijns VE, Wierda CM, van Hoeij M, Horzinek MC. 1996. Exacerbated viral hepatitis in IFN‐gamma receptor‐deficient mice is not suppressed by IL‐12. J Immunol 157: 815–821. [PubMed] [Google Scholar]
  33. Takaoka A, Mitani Y, Suemori H, Sato M, Yokochi T, Noguchi S, Tanaka N, Taniguchi T. 2000. Cross talk between interferon‐gamma and ‐alpha/beta signaling components in caveolar membrane domains. Science 288: 2357–2360. [DOI] [PubMed] [Google Scholar]
  34. Thomas DC, Samuel CE. 1992. Mechanism of interferon action: alpha and gamma interferons differentially affect mRNA levels of the catalytic subunit of protein kinase A and protein Mx in human cells. J Virol 66: 2519–2522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Uetsuka K, Nakayama H, Goto N. 1996. Protective effect of recombinant interferon (IFN)‐alpha/beta on MHV‐2cc‐induced chronic hepatitis in athymic nude mice. Exp Anim 45: 293–297. [DOI] [PubMed] [Google Scholar]
  36. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. 2000. Peginterferon alpha‐2a in patients with chronic hepatitis C. N Engl J Med 343: 1666–1672. [DOI] [PubMed] [Google Scholar]
  37. Zhang X, Hinton DR, Cua DJ, Lai MM, Stohlman SA, Lai MM. 1997. Expression of interferon‐gamma by a coronavirus defective‐interfering RNA vector and its effect on viral replication, spread, and pathogenicity. Virology 233: 327–338. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Medical Virology are provided here courtesy of Wiley

RESOURCES